Inhibiting the assembly of protein-protein interfaces

Current Opinion in Chemical Biology

Volumn 2, Issue 1, 1998, Pages 62-66

  Zutshi, Reena ^a   Brickner, Michelle ^a   Chmielewski, Jean ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN SYNTHESIS INHIBITOR;

ENZYMOLOGY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM; PROTEIN BINDING; PROTEIN CONFORMATION; REVIEW; VIRUS;

HIV; HUMANS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN SYNTHESIS INHIBITORS; SIMPLEXVIRUS; VIRUSES;

EID: 0031993453     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(98)80036-7     Document Type: Article

References (31)

1. Stites W: Protein-protein interactions: interface structure, binding thermodynamics, and mutational analysis. Chem Rev 1997, 97:1233-1250. A thorough review of the multitude of interactions in protein interfaces.
2. Jones S, Thornton JM: Principles of protein-protein interactions. Proc Natl Acad Sci USA 1996, 93:13-20. A thorough review of the multitude of interactions in protein interfaces.
3. Frieden C: Protein-protein interaction and enzymatic activity. Annu Rev Biochem 1971, 40:653-665
4. Heldin C-H: Dimerization of cell surface receptors in signal transduction. Cell 1995, 80:213-223.
5. Gibson W: Structure and assembly of the virion. Intervirology 1996, 39:389-400.
6. Nakabeppu Y, Nathans D: A naturally occurring truncated form of FosB that inhibits Fos/Jun transcriptional activity. Cell 1991, 64:751-759.
7. Benezra R, Davis R, Lockshon D, Turner D, Weintraub H: The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 1990, 61: 49-59.
8. Babe LM, Pichuantes S, Craik CS: Inhibition of HIV protease activity by heterodimer formation. Biochemistry 1991, 30:106-111.
9. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA: Rational design of potent antagonists to the human growth hormone receptor. Science 1992, 256:1677-1680.
10. Wlodawer A, Miller A, Jaskolski M, Sathyanarayana B, Baldwin E, Weber I, Selk L, Clawson L, Schneider J, Kent S: Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science, 1989, 245:616-621.
11. Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W: The inhibition of human immunodeficiency virus proteases by 'interface peptides'. Antiviral Res 1996, 30:155-170. A large data set of small peptide inhibitors of HIV-1 protease dimerization and activity.
12. Zhang Z-Y, Poorman RA, Maggiora LL, Heinrikson RL, Kezdy FJ: Dissociation inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV1 protease by its COOH-terminal tetrapeptide. J Biol Chem 1991, 266:15591-15594.
13. Zutshi R, Franciskovich J, Shultz M, Schweitzer B, Bishop P, Wilson M, Chmielewski J: Targeting the dimerization interface of HIV-1 protease: inhibition with crosslinked interfacial peptides. J Am Chem Soc 1997, 119:4841-4845. Mimics of the dimerization interface of HIV-1 PR are described, in addition to a variety of assays to monitors protease dissociation.
14. Gustchina A, Weber IT: Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins 1991, 10:325-331.
15. Deeks SG, Smith M, Holodniy M, Kahn JO: HIV-1 protease inhibitors. J Am Med Assoc 1997, 277:145-153.
16. Divita G, Restle T, Goody RS, Chermann J-C, Baillon JG: Inhibition of human immunodeficiency virus type 1 revrse transcriptase dimerization using synthetic peptides derived from the connection domain. J Biol Chem 1994, 269:13080-13083.
17. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA: Crystal structure at 3.5 Å resolution of HIV reverse transcriptase complexed with an inhibitor. Science 1992, 256:1783-1790.
18. Bujacz G, Alexandratos J, Zhou-Liu Q, Cläment-Mella C, Wlodawer A: The catalytic domain of human immunodeficiency virus integrase: ordered active site in the F185H mutant. FEBS Lett 1996, 398:175-178.
19. Sourgen F, Maroun RG, Frere V, Bouziane M, Auclair C, Troalen F, Fermandjian S: A synthetic peptide from the human immunodeficiency virus type-1 integrase exhibits coiled-coil properties and interferes with the in vitro integration activity of the enzyme. Eur J Biochem 1996, 240:765-773.
20. Filatov D, Ingemarson R, Graslund A, Thelander L: The role of herpes simplex virus ribonucleotide reductase small subunit carboxyl terminus in subunit interaction. J Biol Chem 1992, 267:15816-15822.
21. Krogsrud RL, Welchner E, Scouten E, Liuzzi M: A solid phase assay for the binding of peptidic subunit association inhibitors to the herpes simplex virus ribonucleotide reductase large subunit. Analyt Biochem 1993, 213:386-394.
22. Liuzzi M, Deziel R, Moss N, Beaulieu P, Bonneau A-M, Bousquet C, Chafouleas JG, Garneau M, Jaramillo J, Krogsrud RL et al.: A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature 1994, 372:695-698.
23. Digard P, Bebrin W, Weisshart K, Coen DM: The extreme C terminus of herpes simplex virus DNA polymerase is crucial for functional interaction with processivity factor UL42 and for viral replication. J Virol 1993, 67:398-406.
24. Digard P, Williams KP, Hensley P, Brooks IS, Dahl CE, Coen DM: Specific inhibition of herpes simplex virus DNA polymerase by helical peptides corresponding to the subunit interface. Proc Natl Acad Sci USA 1995, 92:1456-1460.
25. Hargrave PA, McDowell JH: Molecular Biology of Receptors and Transporters: Receptors. Edited by Friedlander M, Mueckler M. San Diego: Academic Press; 1992:49-98.
26. Martin EL, Rens-Domiano S, Schatz PJ, Hamm HE: Potent peptide analogues of a G protein receptor-binding region obtained with a combinatorial library. J Biol Chem 1996, 271:361-366. A combinatorial approach is described to identify peptide sequences that bind to rhodopsin with high affinity.
27. Skiba NP, Artemyev NO, Hamm HE: The carboxyl terminus of the γ-subunit of rod cGMP phosphodiesterase contains distinct sites of interaction with the enzyme catalytic subunits and the γ-subunit of transducin. J Biol Chem 1995, 270:13210-13215.
28. Krupnick JG, Gurevich VV, Schepers T, Hamm HE, Benovic JL: Arrestin-rhodopsin interaction. J Biol Chem 1994, 269:3226-3232.
29. 2-adrenergic receptors homodimerize, and that the transmembrane domain (TM) VI of the receptor is at the interface. Peptides derived from TM VI were shown to inhibit receptor dimerization.
30. McDowell RS, Blackburn BK, Gadek TR, McGee LR, Rawson T, Reynolds ME, Robarge KD, Somers TC, Thorsett ED, Tischler M, Webb RR II, Venuti MC: From peptide to non-peptide. 2. The de novo design of potent, non-peptidal inhibitors of platelet aggregation based on a benzodiazepinedione scaffold. J Am Chem Soc 1994, 116:5077-5083.
31. McDowell RS, Gadek TR: Structural studies of potent constrained RGD peptides. J Am Chem Soc 1992, 114:9245-9253.